Tirzepatide, a combination of GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, recently approved for obesity, has demonstrated superior efficacy in weight and glucose reduction compared to GLP‐1 RAs alone.11, 12. This evidence concerns the gene GLP1R and obesity disorder.